Clinical Trial Update: Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of PEP005 gel (ingenol mebutate) 0.05% for seborrheic keratosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seborrheic Keratosis

Drugs mentioned

• PEP005 Gel (ingenol mebutate)

Snippet

Sponsor: Peplin | Conditions: Seborrheic Keratosis | Phase 2 | Status: COMPLETED